Myocarditis
Conditions
Keywords
Major Adverse Cardiac Events (MACE), COVID-19 vaccination, Comirnaty (Pfizer/BioNTech) mRNA vaccine, Moderna mRNA vaccine, myopericarditis, health care professionals, COVID-19 booster vaccination, vaccination-induced myocarditis
Brief summary
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
Detailed description
Considering previous reports of cardiovascular adverse events, passive surveillance might not identify all myocarditis/myopericarditis cases after COVID-19 vaccination and it is possible that a mild/subclinical myocarditis might be much more prevalent in the population. This research project has three aims: first, provide novel insights regarding the incidence, patient characteristics and outcome of myocarditis. Second, provide a safety net by active surveillance for myocarditis, allowing early initiation of appropriate therapy. Third, provide reassurance to the public regarding myocarditis, as questions have been raised by critics of the pharmaceutical industry that Phase III studies performed by the pharmaceutical industry may have not appropriately captured adverse events. This study is screening persons undergoing the COVID-19 mRNA booster vaccination of possible development of myocarditis. This approach in detecting myocarditis would help early initiation of the right treatment under close monitoring of the clinical course. Furthermore, this kind of study might also help understand the development of myocarditis and possibly the reasons for sex differences. Myocarditis suspicion is raised when patients present symptoms of acute chest discomfort, myalgia, fever/chills, abnormal ECG, increased concentrations of high-sensitivity cardiac troponin T (hs-cTnT), possibly supported by signs of cardiac inflammation in cMRI (myocardial oedema, myocardial/pericardial late gadolinium enhancement, pericardial effusion). Since the study is performed on health care professionals working in the University Hospital Basel, it is able to monitor more closely the possible side effects of the mRNA vaccination. Consecutive individuals that received a COVID-19 mRNA vaccine booster and undergo a systematic approach to detect myocarditis at the University Hospital Basel will be included.
Interventions
OTHERdata collection in healthcare professionals with COVID-19 mRNA vaccine booster
Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* individuals working at the University Hospital Basel, Switzerland * informed consent available * 16-65 years old
Exclusion criteria
* Refusal to participate at the study * Cardiac events or cardiac surgery within 30 days prior to study (as these could result in prolonged hs-cTnT elevations and interfere with the diagnosis of myocarditis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of myocarditis after mRNA COVID-19 mRNA booster vaccine | Assessment at day 3 (48- 96h) post-vaccination | The primary endpoint is centrally adjudicated myocarditis after mRNA COVID-19 mRNA vaccine by a cardiologist according to current European Society of Cardiology (ESC) guidelines. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with MRI abnormalities after COVID-19 booster | Assessment at day 4 post-vaccination | Number of participants with MRI abnormalities after COVID-19 booster |
| Composite of major adverse cardiac events | 1-month follow-up post-vaccination | MACE is defined as a composite of acute heart failure (requiring admission to a hospital or intra-hospital transfer to the intensive care unit), cardiac death, life-threatening arrhythmia (cardiac arrest, sustained ventricular tachycardia, AV-block III), signs of left bundle branch block (LBBB) within 1 month after mRNA COVID-19 vaccination. |
| Need for hospitalization | At day 4 post-vaccination | Need for hospitalization |
| Number of participants developing symptoms after the COVID-19 booster | Assessment at day 3 (48- 96h) post-vaccination | Number of participants developing symptoms after the COVID-19 booster |
| hs-cTnT/I concentrations on day 4 | At day 4 post-vaccination | hs-cTnT/I concentrations on day 4 |
| Total sum of costs (CHF) | 1-month follow-up post-vaccination | Total sum of costs from involved study personnel, blood sampling, material used and further diagnostic work-up and treatment to estimate the financial value related to future screening of individuals receiving mRNA vaccines. |
| T cell reactivity | Assessment at day 4 post-vaccination | T cell reactivity (against the SARS-CoV2 Spike, protein, myosin) in EDTA blood |
| Need for medical treatment | At day 4 post-vaccination | Medical treatment could include, nonsteroidal anti-inflammatory medication (NSAIDs), use of immunomodulatory therapy such as colchicine (in cases with presumed pericardial inflammation) and intravenous globulins or corticosteroids, paracetamol, or morphine. |
Countries
Switzerland
Outcome results
None listed